Palisade Bio has dosed the first patient in its global Phase 2b ASCENTRA-UC trial testing PALI-2108, a once-daily oral drug for moderate to severe ulcerative colitis. The trial will enroll about 204 patients across approximately 115 sites worldwide, with topline results expected in Q4 2027. PALI-2108 is designed to target inflammation in the gut with potentially improved tolerability compared to similar drugs. Positive early Phase 1 results showed clinical response and remission in a small patient group, supporting further development.
Palisade Bio's Phase 2b ASCENTRA-UC trial has begun dosing patients, aiming to enroll about 204 participants globally. For readers following the health sector, here is Pluang's market snapshot as of Oct 28, 2026 19:11 WIB: out of 150 priced US health stocks, 42 rose and 97 fell. Notable movers include AXGN at USD 43.65 with a 16.52% increase and 100% sell order activity, NUWE at USD 4.71 down 13.42% with 100% sell orders, and BSX at USD 39.07 down 13.29% with 99% sell orders and a typical hold time of 81 days.
Circuit Mind has introduced AVE (Agentic Verification Engine), an AI-powered application that verifies printed circuit board (PCB) schematics against datasheets and internal design rules to catch errors early and avoid expensive respins. AVE compleme...
Grabar Law Office is investigating claims against officers and directors of Erasca, Planet Fitness, PROCEPT BioRobotics, and The Simply Good Foods Company for alleged breaches of fiduciary duties. The investigations focus on misleading statements and...
Circuit Mind secured $25 million in funding, including an $18.5 million Series A led by Norwest, to expand its AI platform that automates and optimizes electronic circuit board design. The platform helps companies reduce design time by up to 90%, cut...
Alvotech, a global biotech company specializing in biosimilars, will release its financial results for the first nine months of 2026 on November 11 after U.S. market close. A live webcast presentation is scheduled for November 12 at noon, where manag...
Sampo Oyj will publish its financial results for the first nine months of 2026 on November 4, 2026, at around 8:30 AM. Alongside the report, supplementary presentation materials will be available on their website. An investor conference call will be ...
